On March 25, 2026, Peijia Medical announced its annual results for the year ended December 31, 2025. During the year, the Group delivered steady revenue growth and continued improvement in operating efficiency, while advancing multiple key pipeline programs. 

For the year ended December 31, 2025, the Group recorded total revenue of RMB712.9 million, representing a year-on-year increase of 15.8%. While maintaining a relatively stable gross margin, the Group continued to strengthen cost discipline and improve operating efficiency, supported by scale expansion and more focused resource allocation. Excluding the losses attributable to the entities comprising the Future Technology Business, the Group's adjusted loss for the year narrowed by 44.1% year on year to RMB110.5 million, reflecting a clear trend of improving underlying profitability.